Dipti Barman

Dipti Barman is a seasoned scientist with extensive experience in chemical biology and drug development. Currently serving as a Senior Scientist II at Turn Biotechnologies since July 2022, Dipti focuses on designing and synthesizing delivery platforms for epigenome reprogramming. Previous roles include Senior Scientist positions at GenEdit and Memorial Sloan Kettering Cancer Center, where Dipti contributed to the synthesis of cationic and block copolymer formulations, as well as developing MbtA inhibitors and novel nucleosides. Dipti has also worked at Weill Cornell Medicine, where expertise in in silico screening and chemical entity synthesis was gained. Early career experiences included founding B&P Chemicals Inc. and conducting research at Alberta Research Chemicals Inc., Rutgers Pharmacy School, the University of Oklahoma, and the University of Missouri, culminating in a Ph.D. in Organometallic Chemistry from the University of Oklahoma.